# MorningSun (NCT05207670)

> A Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab Monotherapy in Participants With Select B-Cell Malignancies

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05207670
- Phase: PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Genentech, Inc.
- Conditions: Non-Hodgkin Lymphoma
- Interventions: Mosunetuzumab (Cohorts A-C); Mosunetuzumab (Cohorts D-E); Tocilizumab
- Enrollment: 320
- Primary outcome: Progression-free survival (PFS) rate at 24 months after the first study treatment (Cohorts A1, A2, and B)
- Primary outcome: Objective response rate (ORR), defined as the proportion of participants with a complete metabolic response (CMR) or partial response (PR), as determined by the investigator according to the Lugano Criteria 2014 (Cohorts C, D, and E)

## Commentary we found

- YouTube: 22
- Podcasts: 6
- X threads: 4

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=morningsun-nct05207670

## Free build

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05207670", "email": "<work email>"}; the inbox owner confirms by the emailed link.